NRXP (NRX Pharmaceuticals) Interest Coverage : No Debt ⁽¹⁾ (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is NRX Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. NRX Pharmaceuticals's Operating Income for the three months ended in Mar. 2025 was $-3.75 Mil. NRX Pharmaceuticals's Interest Expense for the three months ended in Mar. 2025 was $0.00 Mil. NRX Pharmaceuticals has no debt. The higher the ratio, the stronger the company's financial strength is.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for NRX Pharmaceuticals's Interest Coverage or its related term are showing as below:

NRXP's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 119.89
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NRX Pharmaceuticals Interest Coverage Historical Data

The historical data trend for NRX Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

NRX Pharmaceuticals Interest Coverage Chart

NRX Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Coverage

N/A

NRX Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Coverage	Get a 7-Day Free Trial															-	No Debt	N/A	N/A	No Debt

Competitive Comparison of NRX Pharmaceuticals's Interest Coverage

For the Biotechnology subindustry, NRX Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NRX Pharmaceuticals's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where NRX Pharmaceuticals's Interest Coverage falls into.

Save Embed

;

Save Embed

;

NRX Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NRX Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, NRX Pharmaceuticals's Interest Expense was $-0.23 Mil. Its Operating Income was $-18.50 Mil. And its Long-Term Debt & Capital Lease Obligation was $5.01 Mil.

NRX Pharmaceuticals did not have earnings to cover the interest expense.

NRX Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Here, for the three months ended in Mar. 2025, NRX Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-3.75 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

NRX Pharmaceuticals had no debt ⁽¹⁾.

The higher the ratio, the stronger the company's Financial Strength is.

NRX Pharmaceuticals (NAS:NRXP) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

NRX Pharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

NRX Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (NAS:NRXP) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

B1Q:Germany

Address

1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801

Website

https://nrxpharma.com

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Executives

Jonathan C Javitt	director, 10 percent owner, officer: Chief Scientist	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Richard Clavano Narido	officer: Interim CFO	12 HANSEN CT, MORAGA CA 94556
Aaron Gorovitz	director	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Chaim Hurvitz	director	C/O GALMED PHARMACEUTICALS LTD., 8 SHAUL, HAMELECH BLVD, AMOT HAMISHPAT BLDG., TEL AVIV L3 64733
Voorhees Seth Van	officer: Chief Financial Officer	12 HARVEY DRIVE, SHORT HILLS NJ 07078
Stephen H Willard	director, officer: Chief Executive Officer	1201 ORANGE STREET, SUITE 600, WILMINGTON DE 19801
Daniel C. Javitt	10 percent owner	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Patrick John Flynn	director	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Ira S Strassberg	officer: Chief Financial Officer	C/O CONTINENTAL BUILDING PRODUCTS, 12950 WORLDGATE DRIVE, HERNDON VA 20170
Robert Besthof	officer: Chief Comm. & Patient Officer	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Alessandra Daigneault	officer: General Counsel & Secretary	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Herbert Raymond Mcmaster	director	C/O ZOOM VIDEO COMMUNICATIONS, INC., 55 ALMADEN BOULEVARD, 6TH FLOOR, SAN JOSE CA 95113
William Fricker	officer: CFO & Treasurer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Big Rock Partners Sponsor, Llc	10 percent owner	2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483
Richard Ackerman	director, 10 percent owner, officer: President & CEO	2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483